One run, one molecule. The complete picture.
Genomics without Compromise
A new platform, built on a new approach to sequencing. Not to do what's been done better, but to enable what's never been possible.
The Challenge
Today, DNA sequencing is cheap. Its constraints are not.
To detect weak signals, current sequencing technologies amplify the material. The field has been managing the compromises ever since.
Amplification Bias
GC-rich regions, repetitive elements, and structural motifs are systematically over- or under-represented by PCR, distorting the data before sequencing even begins.
Lost Biological Information
Base modifications like methylation are lost before sequencing even begins, destroying the epigenetic signals that require expensive additional workflows to reconstruct.
Workflow Complexity
The full library prep pipeline requires trained personnel and expensive consumables across multiple manual steps, and the cumulative cost of that complexity falls on every single sample.
Incremental Ceilings
Because existing platforms weren't architected for multi-modal sequencing, every new capability — methylation, long reads, structural variation — arrives as a separate, compounding layer of cost and complexity.
The Technology
They amplify the material, we amplify the signal
At the core of SWAN is a plasmonic nanoantenna. Single molecule detection on native genetic material. All the biology, no constraints.
Massively Parallel
Precision nanoscale sensor positioning at manufacturing scale. Billions of sensors, for pennies.
Signal Amplification
An engineered optical hotspot makes single fluorescent molecules thousands of times brighter.
Native Readout
Bases are read one at a time as optical pulses, in real time, from a single molecule.
Read the molecule as it is. Every base, every modification, every length, natively. One platform for the complete molecular picture.
Why Only SWAN
What makes this architecture unreplicable
Swan's advantage isn't a feature but a convergence of physics, nanotechnology, and biology that no platform can replicate by iteration.
Plasmonic Detection Is Not Incremental
Plasmonic nanoantenna signal amplification represents an entirely new approach, not an upgrade. Operating on physics that no existing platform has access to.
DNA Origami as Precision Manufacturing
With programmable molecular self-assembly, SWAN achieves low nanometer precision in nanoparticle and biomolecule positioning at extremely low cost.
Native Molecule, Complete Signal
Because SWAN does not need to copy the molecule, all biological information is retained, without the need for complex and expensive workflows to recover what would otherwise be lost.
Capabilities Are Inherent, Not Bolted On
Capabilities expand without requiring architectural changes, because methylation, long reads, and structural context are inherently supported by the core approach, not added on as separate features.
Platform Vision
One architecture.
Expanding capability.
This is not a single product technology. Each generation of SWAN's platform unlocks new capabilities, all built on the same core approach without requiring architectural changes.
SWAN Gen 1 Platform (in development): Integrated instrument, reagents, and flowcell
Applications
Where this matters most
SWAN's platform is designed to serve applications across the full spectrum of genomics — from near-term clinical diagnostics to research frontiers that require capabilities no current platform can deliver from a single run.
The Team
Scientists and engineers building the next platform
SWAN brings together deep expertise in nanophotonics, DNA nanotechnology, sequencing chemistry, and diagnostics commercialization. We are a globally distributed team united by the conviction that genomics needs a new physical architecture.
Lawrence Lee, PhD
Co-Founder & CEO
Science and technology leadership with deep expertise in molecular self-assembly, bioengineering and DNA nanotechnology. Built the foundational science behind SWAN’s nanoantenna platform.
Morassa Mohseni, PhD
SVP Product, Commercial & Operations
Decades of diagnostics and genomics experience. Previously at Roche Sequencing, Omniome, Ariosa Diagnostics, and Encodia. Bridges science and market.
Min Huang, PhD
Co-Founder & Director of R&D
Lead scientist on sequencing chemistry, polymerase engineering, and nanoantenna-based detection systems. Drives SWAN’s core technology development.
Brock Siegel, PhD
Co-Founder & Board
Seasoned investor and board director with a track record in deep-tech and life-science ventures. Focuses on governance, capital strategy, and market positioning.
William Hyun, PhD
Co-Founder & Board
Experienced deep-tech entrepreneur and company builder. Brings operational expertise in scaling technical ventures from lab to market.
Mike Finney, PhD
Adviser & Board
Genomics industry veteran with executive experience across multiple sequencing platforms. Provides strategic guidance on technology development and commercialization.
Backing and Validation
Trusted by those who back conviction
Key Investors
Supported By
News & Media
Latest News & Media
Let's build the future of sequencing
We're looking for partners, collaborators, and exceptional talent to join us in building the next generation of genomics.